Meningococcal A, C, Y and W-135 polysaccharide-protein conjugate vaccines

Archives of Disease in Childhood

Volumn 92, Issue 10, 2007, Pages 909-915

  Pace, David ^a,b   Pollard, Andrew J ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MENINGOCOCCUS VACCINE; POLYSACCHARIDE VACCINE;

ANTIBODY TITER; BLOOD GROUP TYPING; CLINICAL TRIAL; DRUG CONJUGATION; GUILLAIN BARRE SYNDROME; HUMAN; IMMUNIZATION; MENINGOCOCCOSIS; MORBIDITY; NEISSERIA MENINGITIDIS; NEISSERIACEAE INFECTION; PRIORITY JOURNAL; REVIEW;

ADOLESCENT; AGE FACTORS; AUSTRALIA; CANADA; CHILD; CHILD, PRESCHOOL; FEMALE; GREAT BRITAIN; HUMANS; INFANT; MALE; MENINGITIS, MENINGOCOCCAL; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES;

EID: 35148828105     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/adc.2006.111500     Document Type: Review

References (73)

1. Pollard AJ, Levin M. Vaccines for prevention of meningococcal disease. Pediatr Infect Dis J 2000;19(4):333-44.
2. Martin D, Lopez L, McDowell R. The epidemiology of meningococcal disease in New Zealand in 2004. Report prepared for the Ministry of Health by the Institute of Environmental Science and Research Limited (ESR). Wellington: Ministry of Health, 2005, Available from http://www.moh.govt.nz/ publicationsbytitle (accessed 8 April 2007).
3. Kirsch EA, Barton RP, Kitchen L, et al. Pathophysiology, treatment and outcome of meningococcemia: a review and recent experience. Pediatr Infect Dis J 1996;15(11):967-78.
4. Miller E, Salisbury D, Ramsay ME. Planning, registration and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine 2001;20(Suppl 1):S58-67.
5. Snape M, Stone K, Pace D, et al. Immunogenicity of a quadrivalent meningococcal glycoconjugate vaccine in infants. Abstract presented at the Meningitis Research Foundation's international conference: Meningitis and Septicaemia in Children and Adults, Burden of Illness, Management and Prospects for Prevention 2005, London, UK.
6. Finne J, Leinonen M, Makela PH. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet 1983;2(8346):355-7.
7. World Health Organization. Control of epidemic meningococcal disease. WHO practical guidelines. 2nd edn. Geneva, Switzerland: World Health Organization, 1998, Available from http://www.who.int/en/ (accessed 8 April 2007).
8. Bilukha OO, Rosenstein N. Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2005;54(RR07):1-21.
9. European Union Invasive Bacterial Infections Surveillance Network. 2003 Invasive Neisseria meningitidis in Europe - 2002. Available from www.euibis.org/documents/2002_meningo.pdf (accessed 8 April 2007).
10. CDC. Active bacterial core surveillance. Available from http://www.cdc.gov/ncidod/dbmd/abcs/survreports.htm (accessed 8 April 2007).
11. Achtman M, van der Ende A, Zhu P, et al. Molecular epidemiology of serogroup A meningitis in Moscow, 1969 to 1997. Emerg Infect Dis 2001;7(3):420-7.
12. World Health Organization. WHO report on global surveillance of epidemic-prone infectious diseases, 2000. Available from http://www.who.int/csr/ resources/publications/surveillance/Meningitis.pdf (accessed 8 April 2007).
13. Greenwood BM, Bradley AK, Wall RA. Meningococcal disease and season in sub-Saharan Africa. Lancet 1985;2:829-30.
14. Decosas J, Koama JB. Chronicle of an outbreak foretold: meningococcal meningitis W135 in Burkina Faso. Lancet Infect Dis 2002;2(12):763-5.
15. Moore PS, Reeves MW, Schwartz B, et al. Intercontinental spread of an epidemic group A Neisseria meningitidis strain. Lancet 1989;2(8657):260-3.
16. Popovic T, Sacchi CT, Reeves MW, et al. Neisseria meningitidis serogroup W135 isolates associated with the ET37 complex. Emerg Infect Dis 2000;6(4):428-9.
17. Cartwright KA, Stuart JM, Jones DM, et al. The Stonehouse survey: nasopharyngeal carriage of meningococci and Neisseria lactamica. Epidemiol Infect 1987;99:591-601.
18. Gold R, Goldschneider I, Lepow ML, et al. Carriage of Neisseria meningitidis and Neisseria lactamica in infants and children. J Infect Dis 1978;137(2):112-21.
19. Claus H, Maiden MC, Wilson DJ, et al. Genetic analysis of meningococci carried by children and young adults. J Infect Dis 2005;191(8):1263-71.
20. Yazdankhah SP, Kriz P, Tzanakaki G, et al. Distribution of serogroups and genotypes among disease-associated and carried isolates of Neisseria meningitidis from the Czech Republic, Greece, and Norway. J Clin Microbiol 2004;42(11):5146-53.
21. Maiden MC, Stuart JM, UK Meningococcal Carriage Group. Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet 2002;359(9320):1829-31.
22. Jennings HJ, Bhattacharjee AK, Bundle DR, et al. Structures of the capsular polysaccharides of Neisseria meningitidis as determined by 13C-nuclear magnetic resonance spectroscopy. J Infect Dis 1977;136(Suppl):S78-83.
23. Frosch M, Muller D, Bousset K, et al. Conserved outer membrane protein of Neisseria meningitidis involved in capsule expression. Infect Immun 1992;60(3):798-803.
24. Claus H, Vogel U, Muhlenhoff M, et al. Molecular divergence of the sia locus in different serogroups of Neisseria meningitidis expressing polysialic acid capsules. Mol Gen Genet 1997;257(1):28- 34.
25. Swarney JS, Marfin AA, Edupuganti S, et al. Capsule switching of Neisseria meningitidis. Proc Natl Acad Sci U S A 1997;94(1):271-6.
26. Swartley JS, Liu LJ, Miller YK, et al. Characterization of the gene cassette required for biosynthesis of the (alpha1-→6)-linked N-acetyl-D-mannosamine-1-phosphate capsule of serogroup A Neisseria meningitidis. J Bacteriol 1998;180(6):1533-9.
27. Mothershed EA, Sacchi CT, Whitney AM, et al. Use of real-time PCR to resolve slide agglutination discrepancies in serogroup identification of Neisseria meningitidis. J Clin Microbiol 2004;42(1):320-8.
28. Gold R, Lepow ML, Goldschneider I, et al. Clinical evaluation of group A and group C meningococcal polysaccharide vaccines in infants. J Clin Invest 1975;56(6):1536-47.
29. De Wals P, Deceuninck G, De Serres G, et al. Effectiveness of serogroup C meningococcal polysaccharide vaccine: results from a case-control study in Quebec. Clin Infect Dis 2005;40(8):1116-22.
30. Lepow ML, Goldschneider I, Gold R, et al. Persistence of antibody following immunisation of children with groups A and C meningococcal polysaccharide vaccines. Pediatrics 1977;60(5):673-80.
31. Reingold AL, Broome CV, Hightower AW, et al. Age specific differences in duration of clinical protection after vaccination with meningococcal polysaccharide A vaccine. Lancet 1985;2(8447):114- 18.
32. Morley SL, Pollard AJ. Vaccine prevention of meningococcal disease, coming soon? Vaccine 2001;20(5-6):666-87.
33. Zhang Q, Choo S, Everard J, et al. Mucosal immune responses to meningococcal group C conjugate and group A and C polysaccharide vaccines in adolescents. Infect Immun 2000;68:2692-7.
34. Zhang Q, Lakshman R, Burkinshaw R, et al. Primary and booster mucosal immune responses to meningococcal group A and C conjugate and polysaccharide vaccines administered to university students in the United Kingdom. Infect Immun 2001;69(7):4337-41.
35. MacLennan J, Obara S, Deeks J, et al. Immune response to revaccination with meningococcal A and C polysaccharides in Gambian children following repeated immunization during early childhood. Vaccine 1999;17(23-24):3086-93.
36. Lesinski GB, Westerink MA. Novel vaccine strategies to T-independent antigens. J Microbiol Methods 2001;47:135-49.
37. Booy R, Hodgson S, Carpenter L, et al. Efficacy of Haemophilus influenzae type b conjugate vaccine PRP-T. Lancet 1994;344(8919):362-6.
38. Beuvery EC, Miedema F, van Delft R, et al. Preparation and immunochemical characterization of meningococcal group C polysaccharide-tetanus toxoid conjugates as a new generation of vaccines. Infect Immun 1983;40:39-45.
39. Costantino P, Viti S, Podda A, et al. Development and phase I clinical testing of a conjugate vaccine against meningococcus A and C. Vaccine 1992;10(10):691-8.
40. Rennels M, King J Jr, Ryall R, et al. Dose escalation, safety and immunogenicity study of a tetravalent meningococcal polysaccharide diphtheria conjugate vaccine in toddlers. Pediat Infect Dis J 2002;21(10):978-9.
41. Ramsey ME, Andrews NJ, Trotter CL, et al. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. BMJ 2003;326(7385):365-6.
42. Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med 1969;129(6):1307-26.
43. Andrews N, Borrow R, Miller E. Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England. Clin Diagn Lab Immunol 2003;10(5):780-6.
44. Borrow R, Andrews N, Goldblatt D, et al. Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection. Infect Immun 2001;69(3):1568-73.
45. Borrow R, Goldblatt D, Andrews N, et al. Antibody persistence and immunological memory at age 4 years after meningococcal group C conjugate vaccination in children in the United Kingdom. J Infect Dis 2002;186(9):1353-7.
46. Richmond P, Borrow R, Miller E, et al. Meningococcal serogroup C conjugate vaccine is immunogenic in infancy and primes for memory. J Infect Dis 1999;179(6):1569-72.
47. Snape MD, Kelly DF, Green B, et al. Lack of serum bactericidal activity in preschool children two years after a single dose of serogroup C meningococcal polysaccharide-protein conjugate vaccine. Pediatr Infect Dis J 2005;24(2):128-31.
48. Trotter C, Andrew N, Kaczmarski E, et al. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 2004;364(9431):365-7.
49. Meningitis Vaccine Project. MVP news digest, number 9, first quarter 2006. Available at http://www.meningvax.org/files/Newsletter-2006-Q1-09- EN.pdf (accessed 8 April 2007).
50. Broome CV, Rugh MA, Yada AA, et al. Epidemic group C meningococcal meningitis in Upper Volta, 1979. Bull World Health Organ 1983;61(2):325-30.
51. Anderson EL, Bowers T, Mink CM, et al. Safety and immunogenicity of meningococcal A and C polysaccharide conjugate vaccine in adults. Infect Immun 1994;62(8):3391-5.
52. Lakshman R, Burkinshaw R, Choo S, et al. Prior meningococcal A/C polysaccharide vaccine does not reduce immune responses to conjugate vaccine in young adults. Vaccine 2002;20:3778-82.
53. Chippaux JP, Garba A, Ethevenaux C, et al. Immunogenicity, safely, and memory of different schedules of Neisseria meningitidis A/C-diphtheria toxoid conjugate vaccine in infants in Niger. Vaccine 2004;22(25-26):3303-11.
54. Twumasi PA Jr, Kumah S, Leach A, et al. A trial of a group A plus group C meningococcal polysaccharide-protein conjugate vaccine in African infants. J Infect Dis 1995;171(3):632-8.
55. Fairley CK, Begg N, Borrow R, et al. Conjugate meningococcal serogroup A and C vaccine: reactogenicity and immunogenicity in United Kingdom infants. J Infect Dis 1996;174(6):1360-3.
56. Meningitis Research Foundation of Canada. Vaccines. Available from http://www.meningitis.ca/en/vaccines/index.shtml (accessed 8 April 2007).
57. Campbell JD, Edelman R, King JC Jr, et al. Safety, reactogenicity, and immunogenicity of a tetravalent meningococcal polysaccharide-diphtheria toxoid conjugate vaccine given to healthy adults. J Infect Dis 2002;186(12):1848-51.
58. Renneis M, King J Jr, Ryall R, et al. Dose escalation, safety and immunogenicity study of a tetravalent meninogococcal polysaccharide diphtheria conjugate vaccine in toddlers. Pediatr Infect Dis J 2002;21(10):978-9.
59. Rennels M, King J Jr, Ryall R, et al. Dosage escalation, safety and immunogenicity study of four dosages of a tetravalent meningococcal polysaccharide diphtheria toxoid conjugate vaccine in infants. Pediatr Infect Dis J 2004;23(5):429-35.
60. Keyserling H, Papa T, Koranyi K, et al. Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents. Arch Pediatr Adolesc Med 2005;159(10):907-13.
61. Vu DM, Welsch JA, Zuno-Mitchell P, et al. Antibody persistence 3 years after immunization of adolescents with quadrivalent meningococcal conjugate vaccine. J Infect Dis 2006;193(6):821-8.
62. Pichichero M, Casey J, Blatter M, et al. Comparative trial of the safety and immunogenicity of quadrivalent (A, C, Y, W-135) meningococcal polysaccharide-diphtheria conjugate vaccine versus quadrivalent polysaccharide vaccine in two- to ten-year-old children. Pediatr Infect Dis J 2005;24(1):57-62.
63. Lagos R, Papa T, Munoz A, et al. Safety and immunogenicity of a meningococcal (Groups A, C, Y, W-135) polysaccharide diphtheria toxoid conjugate vaccine in healthy children aged 2 to 10 years in Chile. Human Vaccines 2005;1(6):228-31.
64. Granoff DM, Harris SL. Protective activity of group C anticapsular antibodies elicited in two-year-olds by an investigational quadrivalent Neisseria meningitidis-diphtheria toxoid conjugate vaccine. Pediatr Infect Dis J 2004;23(6):490-7.
65. Granoff DM, Morgan A, Welsch JA. Immunogenicity of an investigational quadrivalent Neisseria meningitidis-diphtheria toxoid conjugate vaccine in 2-year old children. Vaccine 2005;23(34): 4307-14.
66. Granoff DM, Morgan A, Welsch JA. Persistence of group C anticapsular antibodies two to three years after immunization with an investigational quadrivalent Neisseria meningitidis-diphtheria toxoid conjugate vaccine. Pediatr Infect Dis J 2005;24:132-6.
67. Snape MD, Pollard AJ. Meningococcal polysaccharide-protein conjugate vaccines. Lancet Infect Dis 2005;5(1):21-30.
68. Bashir HE, Heath PT, Papa T, et al. Antibody responses to meningococcal (groups A, C, Y and W135) polysaccharide diphtheria toxoid conjugate vaccine in children who previously received meningococcal C conjugate vaccine. Vaccine 2006;24(14):2544-9.
69. Vesikari T, Ceddia F, Karvonen A, et al. Immune response and immunological memory induced by a novel meningococcal ACWY-CRM conjugate vaccine (MenACWY) in toddlers. Poster presented at the 23rd Annual Meeting of the European Society of Paediatric Infectious Diseases, Valencia, Spain, 2005.
70. Centers for Disease Control, Prevention (CDC). Update: Guillain-Barré syndrome among recipients of Menactra meningococcal conjugate vaccine-United States, October 2005-February 2006. MMWR Morb Mortal Wkly Rep 2006;55(13):364-6.
71. Donaldson L, Beasley C, Ridge K. Department of Health. Important changes to the childhood immunisation programme. Available at http://www.dh.gov.uk/en/index.htm (accessed 8 April 2007).
72. Australian Government Department of Health and Ageing. National immunisation programme schedule (NIPS). Available at http://www.immunise.health. gov.au (accessed 8 April 2007).
73. Timen A, van Steenbergen JE. Meningitis group C vaccination campaign in the Netherlands. Eur J Pub Health 2002;12(Suppl 1):22.